Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model.
ipragliflozin
non-alcoholic steatohepatitis
sodium-glucose cotransporter 2 inhibitor
Journal
Yonago acta medica
ISSN: 0513-5710
Titre abrégé: Yonago Acta Med
Pays: Japan
ID NLM: 0414002
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
30
11
2018
accepted:
17
12
2018
entrez:
10
4
2019
pubmed:
10
4
2019
medline:
10
4
2019
Statut:
epublish
Résumé
The options for the treatment of nonalcoholic steatohepatitis (NASH) are limited. We examined the effects of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, on the fatty liver Shionogi (FLS)- FLS- The body weight and hepatic cholesterol and triglyceride levels were significantly decreased in the ipragliflozin group compared with the control group. Hepatic steatosis and fibrosis were significantly ameliorated by the treatment with ipragliflozin. Hepatic infiltration of macrophage, expression levels of 8-hydroxy-2-deoxyguanosine (8-OHdG) and hepatic mRNA levels of ER stress markers were not significantly modulated by the treatment with ipragliflozin. Ipragliflozin can be a therapeutic option for patients with NASH. The precise mechanisms of action need to be clarified in future studies.
Sections du résumé
BACKGROUND
BACKGROUND
The options for the treatment of nonalcoholic steatohepatitis (NASH) are limited. We examined the effects of ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, on the fatty liver Shionogi (FLS)-
METHODS
METHODS
FLS-
RESULTS
RESULTS
The body weight and hepatic cholesterol and triglyceride levels were significantly decreased in the ipragliflozin group compared with the control group. Hepatic steatosis and fibrosis were significantly ameliorated by the treatment with ipragliflozin. Hepatic infiltration of macrophage, expression levels of 8-hydroxy-2-deoxyguanosine (8-OHdG) and hepatic mRNA levels of ER stress markers were not significantly modulated by the treatment with ipragliflozin.
CONCLUSION
CONCLUSIONS
Ipragliflozin can be a therapeutic option for patients with NASH. The precise mechanisms of action need to be clarified in future studies.
Types de publication
Journal Article
Langues
eng
Pagination
30-35Références
Nucl Recept Signal. 2010 Apr 16;8:e002
pubmed: 20414453
Hepatol Res. 2013 May;43(5):547-56
pubmed: 23057725
J Clin Med Res. 2016 Mar;8(3):237-43
pubmed: 26858798
PLoS One. 2016 Mar 15;11(3):e0151511
pubmed: 26977813
Diabetes. 2016 Jul;65(7):2032-8
pubmed: 27207551
Diabetol Metab Syndr. 2016 Jul 26;8:45
pubmed: 27462372
Adv Clin Exp Med. 2017 Jan-Feb;26(1):155-166
pubmed: 28397448
Curr Ther Res Clin Exp. 2017 Jul 08;87:13-19
pubmed: 28912902
Intern Med. 2017 Oct 15;56(20):2739-2744
pubmed: 28924123
J Gastroenterol. 2018 Feb;53(2):181-196
pubmed: 29177681
Hepatology. 2018 Jul;68(1):361-371
pubmed: 29222911
Sci Rep. 2018 Feb 5;8(1):2362
pubmed: 29402900
Int J Mol Sci. 2018 Jul 27;19(8):null
pubmed: 30060458
Diabetologia. 2018 Oct;61(10):2118-2125
pubmed: 30132031
Diabetes Metab. 2018 Dec;44(6):457-464
pubmed: 30266577